# A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

> **NCT03927703** · PHASE3 · COMPLETED · sponsor: **Novan, Inc.** · enrollment: 355 (actual)

## Conditions studied

- Molluscum Contagiosum

## Interventions

- **DRUG:** SB206 12%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03927703
- **Lead sponsor:** Novan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-13
- **Primary completion:** 2019-11-11
- **Final completion:** 2020-02-03
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927703, "A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03927703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*